Metastatic renal cell carcinoma (mRCC) is associated with a poor prognosis. It is traditionally a treatment-resistant disease necessitating multi-modal treatment and close follow-up. We herein report a case of mRCC in a patient who was managed closely by a multi-disciplinary team and still retained a very good performance status and treatment response three years after diagnosis. We highlight the importance of close monitoring, switching systemic therapies at progression, early palliative radiotherapy, and patient education in controlling disease burden and maintaining quality of life in patients with mRCC.
Cureus. 2019 Oct 13*** epublish ***
Michael Yan, Richard Gregg, Aamer Mahmud
Radiation Oncology, Kingston Health Sciences Centre, Kingston, CAN., Oncology, Cancer Centre of Southeastern Ontario at Queen's University, Kingston, CAN., Radiation Oncology, Cancer Centre of Southeastern Ontario at Queen's University, Kingston, CAN.